F
Fernando Dangond
Researcher at Merck Serono
Publications - 106
Citations - 4371
Fernando Dangond is an academic researcher from Merck Serono. The author has contributed to research in topics: Cladribine & Interferon beta-1a. The author has an hindex of 29, co-authored 101 publications receiving 3788 citations. Previous affiliations of Fernando Dangond include Merck KGaA & Bayer.
Papers
More filters
Journal ArticleDOI
A compendium of gene expression in normal human tissues.
Li Li Hsiao,Fernando Dangond,Takumi Yoshida,Robert L. Hong,Roderick V. Jensen,Jatin Misra,William P. Dillon,Kailin F. Lee,Kathryn E. Clark,Peter M. Haverty,Zhiping Weng,George L. Mutter,Matthew P. Frosch,Marcy E. MacDonald,Edgar L. Milford,Christopher P. Crum,Raphael Bueno,Richard E. Pratt,Mamatha Mahadevappa,Janet A. Warrington,Gregory Stephanopoulos,George Stephanopoulos,Steven R. Gullans +22 more
TL;DR: A compendium of gene expression in normal human tissues suitable as a reference for defining basic organ systems biology is created and subsets of tissue-selective genes are identified that define key biological processes characterizing each organ.
Journal ArticleDOI
Expression of costimulatory molecules B7-1 (CD80), B7-2 (CD86), and interleukin 12 cytokine in multiple sclerosis lesions.
Anja Windhagen,J Newcombe,Fernando Dangond,C Strand,M N Woodroofe,M L Cuzner,David A. Hafler +6 more
TL;DR: Findings indicate that an early event in the initiation of MS involves upregulation of B7-1 and IL-12, resulting in conditions that maximally stimulate T cell activation and induction of T helper 1-type immune responses.
Journal ArticleDOI
Sodium phenylbutyrate prolongs survival and regulates expression of anti‐apoptotic genes in transgenic amyotrophic lateral sclerosis mice
Hoon Ryu,Karen L. Smith,Sandra Camelo,Isabel Carreras,Junghee Lee,Antonio Iglesias,Fernando Dangond,Kerry Cormier,Merit Cudkowicz,Robert H. Brown,Robert J. Ferrante +10 more
TL;DR: Evidence is provided that the pharmacological induction of NF‐κB‐dependent transcription and bcl‐2 gene expression is neuroprotective in ALS mice by inhibiting programmed cell death and Phenylbutyrate may provide a novel therapeutic approach for the treatment of patients with ALS.
Journal ArticleDOI
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Sandra Camelo,Antonio Iglesias,Daehee Hwang,Brice Due,Hoon Ryu,Hoon Ryu,Karen L. Smith,Karen L. Smith,Steven G. Gray,Jaime Imitola,German Duran,Basel Assaf,Brett Langley,Samia J. Khoury,George Stephanopoulos,Umberto De Girolami,Rajiv R. Ratan,Robert J. Ferrante,Robert J. Ferrante,Fernando Dangond +19 more
TL;DR: It is demonstrated that the histone deacetylase (HDAC) inhibitor drug trichostatin A (TSA) reduces spinal cord inflammation, demyelination, neuronal and axonal loss and ameliorates disability in the relapsing phase of experimental autoimmune encephalomyelitis (EAE), a model of multiple sclerosis (MS).
Journal ArticleDOI
Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study.
Gavin Giovannoni,Per Soelberg Sørensen,Stuart D. Cook,Kottil Rammohan,Peter Rieckmann,Giancarlo Comi,Fernando Dangond,Abidemi Adeniji,Patrick Vermersch +8 more
TL;DR: Cladribine tablets treatment for 2’ years followed by 2 years’ placebo treatment produced durable clinical benefits similar to 4’years of cladribine treatment with a low risk of severe lymphopenia or clinical worsening.